Transcatheter Left Ventricular Reconstruction in Heart Failure Patients With Prior Anterior Myocardial Infarction: The Prospective ALIVE Trial

This study was funded by BioVentrix Inc. Dr Estep has served as a consultant to Abbott, BioVentrix, Zoll, Getinge, and Procyrion. Dr Stone has received speaker honoraria from Medtronic, Pulnovo, Infraredx, Abiomed, Amgen, and Boehringer Ingelheim; has served as a consultant to Abbott, Daiichi Sankyo, Ablative Solutions, CorFlow, Cardiomech, Robocath, Miracor, Vectorious, Apollo Therapeutics, Elucid Bio, Cardiac Success, Valfix, TherOx, HeartFlow, Neovasc, Ancora, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, HighLife, Elixir, Remote Cardiac Enablement, and Aria; and has equity/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Bios tar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, and Xenter. Dr Stone's employer, Mount Sinai Hospital, has received research grants from Shock wave, Abbott, Abiomed, BioVentrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Vascular Dynamics, Pulnovo, and V-wave. Dr Ben-Yehuda has served as a consultant to BioVentrix. Dr Puri has served as a consultant to BioVentrix. Dr Kao has served on the Scientific Advisory Board of CareDx. Dr Pfeiffer has served as a consultant to AncoraHeart; and has received speaker honoraria from Abbott. Dr Boehmer has received speaker honoraria from BioVentrix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.